CD274 and non-small cell lung carcinoma: The phase II clinical trial (NCT02879760) assessed the efficacy of a vaccine combined with pembrolizumab in patients with squamous and non-squamous NSCLC who had completed at least one cycle of platinum-based chemotherapy and/or at least one treatment with PD-1 or PDL-1 antibody-targeted therapy.